Incyte (INCY) Research & Development (2010 - 2026)
Incyte's (INCY) quarterly Research & Development came in at $516.9 million in Q2 2026, up 4.45% YoY from $494.9 million in Q2 2025, and little changed on a QoQ basis from $515.9 million in Q1 2026.
Incyte (INCY) Research & Development (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Research & Development data on file, last reported at $516.9 million in Q2 2026.
- Quarterly Research & Development rose 4.45% year-over-year to $516.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 21.04% YoY) and the FY2025 annual result came in at $2.1 billion, down 21.36% from the prior year.
- Research & Development held at $516.9 million in Q2 2026, from $515.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.1 billion in Q2 2024 to a low of $17.1 million in Q4 2025.
- A 5-year average of $461.6 million and a median of $440.9 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 184.06% — and 2025, when it plunged 96.33%.
- Tracing INCY's Research & Development over 5 years: stood at $501.4 million in 2022, then dropped by 11.34% to $444.5 million in 2023, then grew by 4.85% to $466.0 million in 2024, then sank by 96.33% to $17.1 million in 2025, then soared by 2923.1% to $516.9 million in 2026.
- The last three Research & Development figures came in at $516.9 million (Q2 2026), $515.9 million (Q1 2026), and $17.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 516.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 516.95 Mn |
| Mar 31, 2026 | 515.90 Mn |
| Dec 31, 2025 | 17.10 Mn |
| Sep 30, 2025 | 506.58 Mn |
| Jun 30, 2025 | 494.92 Mn |
| Mar 31, 2025 | 437.28 Mn |
| Dec 31, 2024 | 466.03 Mn |
| Sep 30, 2024 | 573.17 Mn |
| Jun 30, 2024 | 1.14 Bn |
| Mar 31, 2024 | 429.26 Mn |
| Dec 31, 2023 | 444.49 Mn |
| Sep 30, 2023 | 375.71 Mn |
| Jun 30, 2023 | 400.75 Mn |
| Mar 31, 2023 | 406.64 Mn |
| Dec 31, 2022 | 501.36 Mn |
| Sep 30, 2022 | 384.01 Mn |
| Jun 30, 2022 | 347.20 Mn |
| Mar 31, 2022 | 353.37 Mn |
| Dec 31, 2021 | 472.83 Mn |
| Sep 30, 2021 | 334.95 Mn |